NASDAQ · VTVT
Healthcare · Biotechnology
$31.01
Down-$0.36 (-1.16%)
Updated Oct 8, 2026, 6:24 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VTVT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
VTVT closed at $31.01 after 21 trading sessions, down 6.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $29.95 | $31.495 | $29.86 | $31.01 | 26.12K |
| Oct 6, 2026 | $30.50 | $30.50 | $29.55 | $30.03 | 27.93K |
| Oct 5, 2026 | $31.555 | $31.555 | $30.29 | $30.33 | 14.86K |
| Oct 2, 2026 | $32.20 | $32.32 | $30.57 | $30.57 | 18.02K |
| Oct 1, 2026 | $30.99 | $32.28 | $30.99 | $31.85 | 34.27K |
| Sep 30, 2026 | $30.11 | $31.14 | $29.98 | $30.84 | 30.94K |
| Sep 29, 2026 | $30.34 | $30.69 | $30.00 | $30.00 | 85.14K |
| Sep 28, 2026 | $29.75 | $31.4499 | $29.675 | $30.52 | 111.86K |
| Sep 25, 2026 | $30.60 | $30.91 | $29.79 | $30.21 | 28.79K |
| Sep 24, 2026 | $30.57 | $31.57 | $30.24 | $30.73 | 18.03K |
| Sep 23, 2026 | $31.03 | $31.40 | $30.47 | $30.58 | 18.9K |
| Sep 22, 2026 | $31.32 | $32.3792 | $31.07 | $31.10 | 11.17K |
| Sep 21, 2026 | $31.45 | $32.00 | $31.015 | $31.30 | 22.69K |
| Sep 18, 2026 | $31.15 | $32.09 | $31.05 | $31.80 | 74.37K |
| Sep 17, 2026 | $30.89 | $32.11 | $30.77 | $31.40 | 33.39K |
| Sep 16, 2026 | $30.37 | $30.86 | $29.98 | $30.46 | 91.48K |
| Sep 15, 2026 | $31.30 | $31.90 | $29.76 | $30.46 | 45.34K |
| Sep 14, 2026 | $31.80 | $32.53 | $31.44 | $31.44 | 22.15K |
| Sep 11, 2026 | $32.24 | $32.5399 | $31.29 | $31.97 | 13.72K |
| Sep 10, 2026 | $33.00 | $33.00 | $31.85 | $31.86 | 46.34K |
| Sep 9, 2026 | $32.99 | $34.14 | $32.78 | $33.29 | 39.54K |
The latest Smart Investors Daily articles mentioning VTVT.
Company
Market Activity
Research & News
VTVT research
Company profile and research snapshot.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2026 | BTIG | Buy | — |
| Mar 12, 2026 | Evercore ISI Group | Outperform | — |
| Mar 11, 2026 | BTIG | Buy | — |
| Jan 27, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Feb 28, 2026
VTVT stock outlook: underfollowed T1D catalyst with Phase 3 CATT1 cadisegliatin data due 2H2026, improved timeline and runwayâread more on VTVT here.
Benzinga · Feb 2, 2026
vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the
Benzinga · Jan 27, 2026
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $40 to $49.
zacks.com · Nov 24, 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VTVT.
